Welcome to our dedicated page for EVTCY news (Ticker: EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.
Evotec SE (symbol: EVTCY) is a life science company based in Hamburg, Germany, with a unique business model focused on discovering and developing highly effective therapeutics. The company operates globally with over 5,000 employees and has strategic activities in neurology, oncology, metabolic, and infectious diseases. Evotec's multimodality platform combines innovative technologies, data, and science to create a world-leading co-owned pipeline for innovative therapeutics. The company collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders to deliver cutting-edge pharmaceutical products.
Evotec SE has opened its new J.POD(R) 1 US manufacturing facility in Redmond, Washington, designed for flexible cGMP manufacturing of biologics. This state-of-the-art facility, completed in just 19 months, offers capabilities for late-stage clinical development and commercial supply of drug substances, ranging from kilograms to metric tons. It emphasizes environmental sustainability, with reduced resource consumption compared to traditional facilities. The site is expected to employ around 300 people by the end of 2021, enabling Evotec to support urgent medical needs.
Evotec SE will announce its financial results for the first half of 2021 on August 11, 2021. The announcement will be followed by a conference call to discuss the results and provide a performance update. The call is scheduled for 02:00 pm CEST (08:00 am EST, 01:00 pm GMT). Participants can join via various international dial-in numbers, and a simultaneous slide presentation will be available online. Replay options for the conference call will be provided for seven days, and the on-demand version of the webcast will be accessible on Evotec's website.
Evotec announces positive Phase IIb results for eliapixant (BAY1817080), a P2X3 receptor antagonist, aimed at treating refractory chronic cough. The trial demonstrated a statistically significant improvement in cough frequency over placebo after 12 weeks. The safety and tolerability profile of the drug was favorable. Evotec stands to receive a financial milestone payment upon Bayer initiating a Phase III study, as per their 2012 agreement. Further details are expected from Bayer.
Evotec SE has confidentially submitted a Registration Statement on Form F-1 to the U.S. SEC for a proposed offering of shares represented by American Depositary Shares (ADSs). The final number of ADSs and their pricing are yet to be determined. This move is intended to secure a secondary listing on the Nasdaq Global Select Market under the ticker symbol EVO. The anticipated trading start is in the second half of 2021, pending SEC approval.
Evotec has acquired the Verona site from GSK, enabling significant long-term growth opportunities. The site will be renamed Campus Levi-Montalcini to honor Nobel laureate Rita Levi-Montalcini. This facility is a fully integrated R&D powerhouse providing comprehensive drug discovery services, including clinical development and manufacturing. Currently employing around 750 staff, this acquisition strengthens Evotec's capabilities in Italy and aligns with their strategic framework, Action Plan 2025. Financial details of the acquisition were not disclosed.
Evotec SE successfully held its virtual Annual General Meeting 2021, with shareholders approving all management proposals, including financial strategies and appointments. Key highlights include the election of Dr. Constanze Ulmer-Eilfort to the Supervisory Board, replacing Prof. Dr. Wolfgang Plischke, who resigned. The meeting also authorized a new capital plan, setting Authorized Capital 2021 at 20% of share capital. 65.17% of registered capital participated in the vote, indicating strong shareholder engagement and support for the company's strategic direction.
Evotec has launched the PRROTECT initiative aimed at enhancing global pandemic preparedness and rapid response capabilities. This comprehensive program focuses on developing effective therapeutics, including neutralizing antibodies, using advanced technologies like AI and ML. The initiative involves the creation of a multimodal pipeline targeting viruses identified by the WHO, alongside a flexible manufacturing platform for swift production. Evotec anticipates clinical data from PRROTECT by 2022, aiming for collaboration with global partners for a robust response to future pandemics.
Evotec SE reported strong financial results for Q1 2021, with group revenues rising by 11% to €133.1 million compared to Q1 2020. The base business saw growth of 28% when adjusted for currency effects. With a solid balance sheet and net debt of €56 million, the company plans to continue its growth trajectory under the Action Plan 2025, targeting revenues over €1 billion by 2025. Positive developments include new partnerships and a robust pipeline, while adjusted EBITDA was €21.1 million, down from €30 million in the prior year due to increased R&D expenses.
Evotec SE will release its financial results for Q1 2021 on May 11, 2021. A conference call is scheduled for 02:00 pm CET to discuss these results and provide performance updates. Participants can join via phone or an audio webcast available on their homepage. A replay of the call will be accessible for seven days. The company is a leader in drug discovery and has over 100 co-owned product opportunities, collaborating with top names in the pharmaceutical industry.
Evotec has partnered with the University Hospital Erlangen to analyze biospecimens from over 5,000 chronic kidney disease (CKD) patients in the German Chronic Kidney Disease (GCKD) cohort study. Using Evotec's EVOpanOmics and EVOpanHunter platforms, the collaboration aims to create a comprehensive molecular patient database, enhancing the understanding of CKD mechanisms and potential treatments. The partnership extends the GCKD study beyond its original 10-year term, promising novel insights for precision medicine in CKD.
FAQ
Where is Evotec SE based?
What is Evotec SE's business model?
How many employees does Evotec SE have?
What are Evotec SE's strategic activities?
Who does Evotec SE collaborate with?
